Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Apr 2025: Trial started, NCT06935188
  2. 20 Apr 2025: Trial registered, NCT06935188

The trials

NCT06935188: Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

State
Under way
Phase
Phase 2
People
98 planned
Started
17 Apr 2025
Primary completion
31 Dec 2028
Arms
Dalpicilib combined with cetuximab
Results
None posted
  1. 17 Apr 2025: Trial started
  2. 20 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.